For instance, CAR-T cell therapies targeting HCC-associated antigens such as GPC3 and AFP have demonstrated acceptable safety profiles and preliminary efficacy in early-phase clinical trials (43). This evidence concerns the gene GPC3 and hepatocellular carcinoma.